Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cord blood-derived CAR-T cells (Henan Cancer Hospital)
- Development stage
- Unknown
- Lead developer
- Henan Cancer Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Cord blood-derived CAR-T cells (Henan Cancer Hospital) is an investigational allogeneic cell therapy being developed for the treatment of relapsed or refractory B-cell malignancies, including B-cell leukemia and B-cell lymphoma. Unlike traditional autologous CAR-T therapies that utilize a patient's own T cells, this product uses T cells harvested from umbilical cord blood, which are genetically engineered to express a chimeric antigen receptor (CAR) targeting B-cell specific antigens, typically CD19. This approach is specifically being evaluated for patients who have failed prior autologous CAR-T cell therapy or for whom autologous CAR-T cells cannot be successfully manufactured. By utilizing cord blood as a starting material, this therapy explores an alternative to patient-derived cells, potentially offering a more readily available treatment option with T cells that may possess a more naive phenotype and a lower risk of graft-versus-host disease (GvHD) compared to adult peripheral blood-derived allogeneic sources.
- Other names
- Cord blood-derived CAR-T cellsCB-CAR-T cellsCord blood-derived CD19 CAR-T cells
02
Targets
Beyond the preview
Go deeper on Cord blood-derived CAR-T cells (Henan Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cord blood-derived CAR-T cells (Henan Cancer Hospital).